A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC)
Latest Information Update: 05 Nov 2024
Price :
$35 *
At a glance
- Drugs Nadofaragene-firadenovec (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUNAR
- Sponsors Ferring Pharmaceuticals
- 05 Nov 2024 New trial record